We recently covered Uber and some of the headwinds they are facing. Since this research was released, few to none of the headwinds have been adequately addressed and the share price has fallen 9% from $45. Uber is expected to release its quarterly earnings after market close today, but what should we expect to see?
Like many tech giants eager to publicly list, Uber has been running massive losses. Analysts from FactSet are expecting an adjusted net loss of $1.08 billion and revenue of $2.98 billion after the bell today. The consensus from Wallstreet appears to be coming in at a $1.26 loss per share as Bloomberg has stated. The story gets a different spin from Uber who has communicated in its filings with the SEC that it anticipates a net loss in the ball park of $1 billion to $1.1 billion for the quarter. This filing also reveals their anticipated revenue to be roughly $3 billion to $3.1 billion, a climb from $2.6 billion when looking at the quarter from a year ago.
Why The Loss?
Uber has stated its losses are due to their investment in various opportunities as discussed in our previous article. The company intends to position itself in the autonomous space and other emerging opportunities. While this may prove beneficial to Uber in a long term lens, the data strongly suggests it will point short term financials toward significant continued losses. Interested parties should pay attention to the Uber Investor Relations Page for their press release and link to conference call after the close of the markets on May 30th.
For the complete analysis of Ubers IPO, please read our piece: Will Uber Make You Money in the Stock Market?
I/we have no position in any of the stock(s) mentioned.
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.